◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › 0-9 › 0474

Aceso Life Science Group Limited (0474) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Industrials · Rental & Leasing Services · DATA UPDATED 2026-10-02

Aceso Life Science Group Limited (0474) operates in the Rental & Leasing Services industry and is headquartered in Wan Chai, Hong Kong with about 28 employees. Its market capitalization is roughly HK$1 billion. In the fiscal year ended 2026-03-31, 0474 reported HK$58M in revenue and HK$338M in net income.

Aceso Life Science Group Limited, an investment holding company, engages in the financial services, property leasing and development, and construction machinery businesses in Hong Kong and the United Kingdom.

Interactive charts & full statements →

0474 Revenue & Earnings History — Annual Income Statement

Income statement2026-03-312025-03-312024-03-312023-03-312022-03-31
Total RevenueHK$58MHK$50MHK$228MHK$312M—
Gross Profit—HK$90MHK$117MHK$141MHK$162M
Operating Income (EBIT)(HK$23M)(HK$14M)(HK$34M)HK$16M—
Net IncomeHK$338M(HK$757M)(HK$462M)(HK$264M)—

HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

0474 Free Cash Flow History

0474 Balance Sheet History

Balance sheet2026-03-312025-03-312024-03-312023-03-312022-03-31
Total AssetsHK$1.8BHK$3.2BHK$4.8BHK$6.3B—
Total LiabilitiesHK$1.3BHK$2.5BHK$3.0BHK$3.7B—

HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 0474 viewer.

Other Companies in Rental & Leasing Services

← 0472All “0-9” companies0475 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.